Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $1.75
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.75 to $1.75.
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.75 to $1.75.